


In the Claims:


1-53. Cancelled.

54. Cancelled


55. (Previously presented) The compound according to claim 88 wherein B is




56. (Currently amended) The compound according to claim 55 wherein R³ is



57. (Previously presented) The compound according to claim 56 wherein R is F, Cl, Br, I,




58. (Previously presented) The compound according to claim 56 wherein R is CH₃, R³ is



59. (Previously presented) The compound according to claim 58 wherein R^{3a} and R^{3b} are both H.

60. (Previously presented) The compound according to claim 58 wherein R^2 is H.


61. (Previously presented) The compound according to claim 88 which is



62. (Previously presented) The compound according to claim 61 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.


63. (Previously presented) The compound according to claim 61 wherein R^2 is H.

64. (Previously presented) The compound according to claim 88 wherein B is



65. (Previously presented) The compound according to claim 64 wherein R^3 is $-(CH_2)_n-C\equiv C-R_a$ and n is 0.

66. (Previously presented) The compound according to claim 65 wherein R is H, F, Cl,




67. (Previously presented) The compound according to claim 64 wherein R is CH₃, R³ is -(CH₂)_n-C≡C-R_a, n is 0 and R_a is H.

68. (Previously presented) The compound according to claim 67 wherein R^{3a} and R^{3b} are both H.


69. (Previously presented) The compound according to claim 68 wherein R² is H.

70. Cancelled.

71. (Previously presented) The composition according to claim 89 wherein B is



72. (Currently amended) The composition according to claim 71 wherein R³ is



73. (Previously presented) The composition according to claim 72 wherein R is F, Cl, Br,

I, C₁-C₃ alkyl, -C≡C-R_a, or and
X is H, C₁-C₄ alkyl, F, Cl, Br or I.


74. (Previously presented) The composition according to claim 71 wherein R is CH₃, R³

is $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$, n is 0 and R_a is H.

75. (Previously presented) The composition according to claim 74 wherein R^{3a} and R^{3b} are both H.

76. (Previously presented) The composition according to claim 75 wherein R^2 is H.


77. (Previously presented) The composition according to claim 89 wherein said compound is



78. (Previously presented) The composition according to claim 77 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.


79. (Previously presented) The composition according to claim 77 wherein R^2 is H.

80. (Previously presented) The composition according to claim 89 wherein B is



81. (Previously presented) The composition according to claim 80 wherein R^3 is $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$ and n is 0.

82. (Previously presented) The composition according to claim 81 wherein R is H, F, Cl,




X is H, C₁-C₄ alkyl, F, Cl, Br or I.

83. (Previously presented) The composition according to claim 80 wherein R is CH₃, R³ is -(CH₂)_n-C≡C-R_a, n is 0 and R_a is H.

84. (Previously presented) The composition according to claim 83 wherein R^{3a} and R^{3b} are both H.

85. (Previously presented) The composition according to claim 84 wherein R² is H.

86. (Previously presented) The composition according to claim 89 wherein said compound is






Where R¹ is H or an acyl group; and

R² is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

87. (Previously presented) The composition according to claim 86 wherein R¹ is H and R² is H.

88. (Currently amended) A compound according to the formula:




Wherein B is

or

;


R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,




X is H, C₁-C₄ alkyl, F, Cl, Br or I;

R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



or





group;

Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate,

carbonate or urethane group with the adjacent moiety;


R^8 is H or a C_1 - C_{20} alkyl or ether group;

R^3 is a C_3 or C_4 alkyl group, or a ~~$(CH_2)_n-C=C-R_a$~~ , ~~$(CH_2)_n-C\equiv C-R_a$~~ group;



when B is —

, and R^3 is a C_3 or C_4 alkyl group or a ~~$(CH_2)_n-C=C-R_a$~~



group when B is —

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or $-C_1$ - C_4 alkyl;




Y is H, F, Cl, Br, I or $-C_1$ - C_4 alkyl;

k is 0, 1 or 2; and

n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

89. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:




Wherein B is

or

;


R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,




X is H, C₁-C₄ alkyl, F, Cl, Br or I;

R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



or





group;

Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;


R⁸ is H or a C₁-C₂₀ alkyl or ether group;

R^3 is a C_3 or C_4 alkyl group, or a ~~$-(CH_2)_n-C\equiv C-R_a$, $-(CH_2)_n-C\equiv C-R_a$~~ group;



when B is —

~~and R^3 is a C_3 or C_4 alkyl group or a $-(CH_2)_n-C\equiv C-R_a$~~



~~group when B is~~

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or $-C_1-C_4$ alkyl;



Y is H, F, Cl, Br, I or $-C_1-C_4$ alkyl;

k is 0, 1 or 2; and



n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.

90. (Previously presented) A compound according to the formula:




Wherein B is

R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,  or  ;


X is H, C₁-C₄ alkyl, F, Cl, Br or I;

R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a




or



group;

Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;



R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or $-C_1-C_4$ alkyl;



Y is H, F, Cl, Br, I or $-C_1-C_4$ alkyl;

k is 0, 1 or 2; and

n is 3, 4 or 5;


or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

91. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:



Wherein B is


R is H, F, Cl, Br, I, C_1-C_4 alkyl, $-C\equiv N$, $-C\equiv C-R_a$,



X is H, C₁-C₄ alkyl, F, Cl, Br or I;


R¹ is H, an acyl group, a C₁—C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁—C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;



R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or -C₁-C₄ alkyl;

Y is H, F, Cl, Br, I or -C₁-C₄ alkyl;

k is 0, 1 or 2; and

n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.